Pfizer fight with Starboard heats up, hedge fund alleges executive pressure
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the U.S. drugmaker to investigate actions by its board, after two former executives backed out of its campaign against the company.
Pfizer, FDA and hemophilia B
Investors shrugged as Illumina pressed its case for building on its longtime leadership in next-generation sequencing, ...
On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...
Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 7. David ...
2don MSNOpinion
Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback